Graphite Bio, Inc. (GRPH): Price and Financial Metrics


Graphite Bio, Inc. (GRPH): $2.34

0.08 (+3.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GRPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GRPH Stock Price Chart Interactive Chart >

Price chart for GRPH

GRPH Price/Volume Stats

Current price $2.34 52-week high $34.00
Prev. close $2.26 52-week low $2.07
Day low $2.20 Volume 441,600
Day high $2.37 Avg. volume 424,284
50-day MA $4.01 Dividend yield N/A
200-day MA $10.49 Market Cap 135.65M

Graphite Bio, Inc. (GRPH) Company Bio


Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.


GRPH Latest News Stream


Event/Time News Detail
Loading, please wait...

GRPH Latest Social Stream


Loading social stream, please wait...

View Full GRPH Social Stream

Latest GRPH News From Around the Web

Below are the latest news stories about Graphite Bio Inc that investors may wish to consider to help them evaluate GRPH as an investment opportunity.

Is a Surprise Coming for Graphite Bio (GRPH) This Earnings Season?

Graphite Bio (GRPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 8, 2022

Graphite Bio Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., January 27, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced participation in the following upcoming investor conferences:

Yahoo | January 27, 2022

Expanding gene editing firm Graphite Bio signs new lease in South San Francisco

The new lease represents a significant expansion the company, which currently occupies less than 20,000 square feet in South San Francisco.

Yahoo | January 26, 2022

Graphite Bio, Inc.s (NASDAQ:GRPH) Lock-Up Period Set To Expire on December 22nd

Graphite Bios (NASDAQ:GRPH) lock-up period is set to expire on Wednesday, December 22nd. Graphite Bio had issued 14,000,000 shares in its initial public offering on June 25th. The total size of the offering was $238,000,000 based on an initial share price of $17.00. After the expiration of the companys lock-up period, restrictions preventing major shareholders []

Dakota Financial News | December 22, 2021

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #ASH21--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today presented a trial-in-progress poster for the companys Phase 1/2 CEDAR trial for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease (SCD). The poster is being presented at the 63rd American As

Business Wire | December 11, 2021

Read More 'GRPH' Stories Here

GRPH Price Returns

1-mo -41.79%
3-mo -74.57%
6-mo -74.06%
1-year N/A
3-year N/A
5-year N/A
YTD -81.17%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7858 seconds.